Overview

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6 mg sumatriptan. Healthy Individuals will be enrolled for a series of 3 injections over 2 days. Assessment of Local Site Signs will be recorded for up to 5 days, as needed.
Phase:
Phase 1
Details
Lead Sponsor:
Zogenix, Inc.
Treatments:
Sumatriptan